ARTELO BIOSCIENCES, INC. 8-K

What Happened

• Artelo Biosciences, Inc. announced a one-for-three (1-for-3) reverse stock split of its common stock, effective March 10, 2026. As a result, every three pre-split shares were combined into one post-split share.
• The company republished its audited financial statements for the fiscal years ended December 31, 2024 and 2025 to reflect the change in total par value caused by the Reverse Split; those audited statements are included as Exhibit 99.1 to the 8-K and are incorporated by reference.

Key Details

• Outstanding common shares were reduced from 2,124,772 to approximately 708,323 after the Reverse Split.
• Authorized common shares were reduced from 500,000,000 to 166,666,667; authorized preferred shares were reduced from 69,444 to 23,148.
• Par value per share remained unchanged at $0.001 per share.
• Effective date of the Reverse Split: March 10, 2026. Audited financials for FY 2024 and FY 2025 are republished in Exhibit 99.1.

Why It Matters

• The reverse stock split consolidates the company’s share count and will increase the stock’s per-share quoted price proportionally; it does not change each shareholder’s percentage ownership or the par value per share.
• The republished audited financial statements adjust reported totals to reflect the new total par value, so investors and analysts should use the updated filings for share-count, per-share, and capitalization figures when evaluating the company’s recent financials.